Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yang Yin Fu Zheng Therapy in HBV-Associated HCC
NCT02927626Phase 1Completed
- Sponsor
- Beijing Ditan Hospital
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- HM (Herbal Medicine), Combination therapy
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Yangyin Fuzheng Jiedu Prescription in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Survival rate at 2 years. Started Aug 2016; status: completed.
02
Drugs
Yangyin Fuzheng Jiedu Prescription
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02927626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927626.